Rights Issue Over-subscribed
Gothenburg, Sweden, December 8, 2009
Rights issue was over-subscribed
Biolin Scientific has completed a rights issue of shares with the subscription time ending on December 2, 2009. The rights issue was over-sub-scribed with about 89 %.
”Through the rights issue, Biolin Scientific receives the capital needed to continue the good growth experienced over the last years. We thank our shareholders for their support and confidence.” says Fredrik Lindgren, CEO of Biolin Scientific.
Biolin Scientific has completed a rights issue of shares. The proceeds from the rights issue are intended to finance potential complementary acquisitions, investments in product development and in the sales organization, and an increase in working capital, but may also be used for other kinds of investments or to refinance credits.
The rights issue means that 1 new share is issued at an issue price of SKr 6 for every 5 existing shares, leading to the issue of approximately 4 million new shares and providing proceeds of about SKr 24 million. After the rights issue, the total number of shares in Biolin Scientific is approximately 24,1 million.
Of the shares issued, over 97 % were subscribed for by the use of subscription rights. In addition, there were subscriptions without the use of subscription rights for a number of shares corresponding to about 92 % of the number of shares issued. Consequentially, the rights issue was over-subscribed with about 89 %.
The equity rights deriving from the subscription of shares have been listed and are traded on NASDAQ OMX in Stockholm.
The board of directors has made a resolution to allocate the shares, corresponding to about 3 % of the shares issued, that were not subscribed for by the use of subscription rights. These shares were allocated to subscribers that had subscribed by the use of subscription rights, in proportion to the number of subscription rights that had been used. Subscribers who have received allocation will be notified when receiving payment instructions for the allocated shares.
For further information, please contact Fredrik Lindgren, CEO of Biolin Scientific.
| || || |
|CONTACT || ||COMPANY INFORMATION |
|Fredrik Lindgren || ||Biolin Scientific AB (publ) |
|CEO of Biolin Scientific AB (publ) || ||Hängpilsgatan 7 |
|+46 705-61 61 77 || ||SE-426 77 Västra Frölunda |
|firstname.lastname@example.org || ||Sweden |
| || ||Telephone: +46 31 769 7690 |
| || ||Fax: +46 31 69 80 40 |
|PRODUCTS || ||Company number: 556249-4293 |
|www.q-sense.com || ||E-mail: email@example.com |
|www.ksvltd.com || ||Web: www.biolinscientific.com |
|www.nima.co.uk || || |
|www.attension.com || ||THE SHARE |
|www.osstell.com || ||Nasdaq OMX Small Cap in Sweden |
| || ||Stock ticker: BLIN |
| || || |
|BIOLIN SCIENTIFIC IN BRIEF || || |
|Biolin Scientific is an analytical instruments provider focused on the nano-scale study of interfaces. |
|Our customers are primarily researchers within academic research, research institutes and the industrial sector |